Squarepoint
DNTH icon

Squarepoint’s Dianthus Therapeutics DNTH Stock Holding History

Squarepoint’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$363K – 4610
2025
Q1 		$363K Buy
+20,000
New +$441K ﹤0.01% 3585

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint's DNTH Position: Q1 2026 in Review

Squarepoint reduced its Dianthus Therapeutics (DNTH) stake by 81% in Q1 2026, selling an estimated $9.75M and leaving 38,738 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

Squarepoint first reported a position in DNTH in Q1 2020 and has held it in 14 quarters since. The position peaked at $8.54M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Squarepoint held 38,738 shares of Dianthus Therapeutics worth $3.25M as of Q1 2026.
  • Squarepoint sold 168,381 Dianthus Therapeutics shares in Q1 2026, an estimated $9.75M.
  • Dianthus Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1825 holding.
  • Squarepoint first reported a position in Dianthus Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • Squarepoint's Dianthus Therapeutics position peaked at $8.54M in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.